Taysha Gene Therapies Inc
TSHA
Get informed when a big investor buys or sells
+ FollowMarket Cap$1.48B
Close$
$0.31
93.3% downside
Current Fair Value
93.3% downsideOvervalued by 93.3% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $1.48 Billion |
|---|---|
| Enterprise Value | $1.08 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-0.34 |
| Beta | 1.17 |
| Outstanding Shares | 369,044,040 |
Return
| Return on Equity | -38.64% |
|---|---|
| Return on Assets | -31.81% |
| Return on Invested Capital | -34.37% |
Valuation & Multiples
| P/E Ratio | -10.96 |
|---|---|
| PEG | -14.91 |
| Price to Sales | - |
| Price to Book Ratio | 4.63 |
| Enterprise Value to Revenue | 197.1 |
| Enterprise Value to EBIT | -7.08 |
| Enterprise Value to Net Income | -8 |
| Total Debt to Enterprise | 0.05 |
| Debt to Equity | 0.14 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 17, 2026
EPS Estimate
$-0.12
Average shareholder expectationRevenue Estimate
$680,000
Average shareholder expectationNext Earnings Call
Expected Date
November 3, 2026
EPS Estimate
$-0.14
Average shareholder expectationRevenue Estimate
$755,556
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.2254▼ 2.38% |
|---|---|
| Total Calls | 711,200▲ 142.40% |
| Total Puts | 160,300▲ 119.29% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 81.77%▲ 9.32% |
|---|---|
| Total Invested | $2.07B▲ 72.02% |
| Investors Holding | 216▲ 20.00% |
ESG Score
No data
About Taysha Gene Therapies Inc
38 employeesTaysha Gene Therapies is on a mission to eradicate monogenic CNS disease. With a singular focus on developing curative medicines, Taysha aims to rapidly translate our treatments from bench to bedside. Taysha Gene Therapies has combined i...